Invesco Pharmaceuticals ETF
PJP
119 hedge funds and large institutions have $151M invested in Invesco Pharmaceuticals ETF in 2026 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 33 increasing their positions, 21 reducing their positions, and 11 closing their positions.
155% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 11
118% more capital invested
Capital invested by funds: $69.2M → $151M (+$81.8M)
57% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 21
15.89% more ownership
Funds ownership: 21.99% → 37.88% (+16%)
13% more funds holding
Funds holding: 105 → 119 (+14)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $259K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$24.4M |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
+$23.4M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$5.51M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$5.45M |
| 5 |
CI
Cavalier Investments
Alpharetta,
Georgia
|
+$4.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WI
WBI Investments
Red Bank,
New Jersey
|
-$739K |
| 2 |
IDA
Intelligence Driven Advisers
Carlsbad,
California
|
-$565K |
| 3 |
HAS
HBW Advisory Services
Simi Valley,
California
|
-$533K |
| 4 |
GC
Grimes & Company
Westborough,
Massachusetts
|
-$502K |
| 5 |
BlackRock
New York
|
-$367K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Mirae Asset Global Investments
Seoul,
South Korea
| – | -$167K | -1,595 | Closed |
|
127
Citigroup
New York
| – | -$24.6K | -235 | Closed |
|
|
MCM
128
MAI Capital Management
Independence,
Ohio
| – | -$20.7K | -198 | Closed |
|
|
1NWS
129
1 North Wealth Services
Annapolis,
Maryland
| – | -$3.24K | -31 | Closed |
|
|
DAM
130
Delta Asset Management
Memphis,
Tennessee
| – | -$2.61K | -25 | Closed |
|
|
PA
131
Parallel Advisors
San Francisco,
California
| – | -$1.72K | -16 | Closed |
|
PJP Hedge Fund Activity: Q1 2026 in Review
119 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Invesco Pharmaceuticals ETF (PJP) for Q1 2026, worth a combined $151M — up 118% from $69.2M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new PJP positions and 11 closed out — a net gain of 17 holders — while 33 added to existing stakes and 21 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $24.4M. The largest seller was WBI Investments, exiting entirely with an estimated $739K sold.
- 119 institutional investors held Invesco Pharmaceuticals ETF (PJP) as of Q1 2026, up from 105 in Q4 2025.
- Funds reported $151M of Invesco Pharmaceuticals ETF stock for Q1 2026, up 118% quarter-over-quarter.
- 28 funds opened new Invesco Pharmaceuticals ETF positions in Q1 2026 and 11 closed out, a net change of +17 holders.
- The largest Invesco Pharmaceuticals ETF buyer in Q1 2026 was Morgan Stanley, an estimated $24.4M added.
- The largest Invesco Pharmaceuticals ETF seller in Q1 2026 was WBI Investments, an estimated $739K sold.
Based on aggregated 13F filings for Q1 2026.